prostate cancer | Research | Treatment | 8 pages | source: Journal of the American Medical Association (JAMA) | Added May 09, 2019
The association between kidney failure and hormone therapy in prostate cancer
This study examined whether androgen deprivation therapy given as treatment for prostate cancer patients increases the risk of kidney injury.
prostate cancer | Research | 8 pages | source: European Urology | Added May 07, 2019
ADT safe with co morbidities ?
This study investigated the risk of heart attacks and diabetes among prostate cancer patients, with and without co morbidities, receiving androgen deprivation therapy (ADT).
prostate cancer | Research | Treatment | 11 pages | source: British Journal of Cancer | Added Apr 19, 2019
Parenteral estrogen safe and effective as androgen deprivation therapy
This review evaluated the efficacy and safety of parenteral estrogen therapy among prostate cancer patients undergoing androgen deprivation therapy.
prostate cancer | Research | Treatment | 9 pages | source: World Journal of Urology | Added Apr 04, 2019
Reviewing the cardicovascular effects of androgen deprivation therapy in prostate cancer
The authors aimed to determine whether patients who received androgen deprivation therapy were more at risk of experiencing cardiovascular events.
prostate cancer | Research | 10 pages | source: European Urology | Added Apr 02, 2019
How long should hormonal therapy continue in patients who have received postprostatectomy radiotherapy?
This study examined how long hormonal therapy should continue in patients who have received radiotherapy after prostate removal surgery (prostatectomy). This study concluded that patients with a higher number of risk risk factors should receive HT for a longer period of time.
prostate cancer | Research | Treatment | 13 pages | source: Journal of clinical oncology | Added Mar 14, 2019
More effective androgen blockade possible?
This study examined the effectiveness of combined androgen blockade in the treatment of prostate cancer.
prostate cancer | Research | 9 pages | source: British Journal of Cancer | Added Mar 11, 2019
Psychological and physical therapy can improve quality of life
This article examined the use of a physical and psychosocial rehabilitation program to improve urinary dysfunction and patient quality of life following radiotherapy for the treatment of prostate cancer.
prostate cancer | Research | Treatment | 8 pages | source: Urology | Added Feb 20, 2019
Continuous versus intermittent androgen deprivation therapy
This study compared the efficacy of intermittent and continuous androgen deprivation therapy and their affect on quality of life.
prostate cancer | Research | Treatment | Guidelines | 10 pages | source: Journal of clinical oncology | Added Feb 15, 2019
Preventing nausea and vomiting during chemotherapy
This review was conducted in an effort to update current guidelines for the prevention of nausea and vomiting in patients receiving chemotherapy.
According to this update by the American Society of Clinical Oncology, all patients who receive highly emetogenic chemotherapies (treatments known to cause nausea and vomiting) should be offered a three-drug combination of an NK1-receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone.
NEPA combination (Akynzeo) plus dexamethasone is a safe and effective treatment option in this setting.
